How Secukinumab Works for Hidradenitis Suppurativa
Secukinumab is a human monoclonal antibody that selectively blocks interleukin-17A (IL-17A), a key inflammatory cytokine that drives the painful nodules, abscesses, and tunnels characteristic of hidradenitis suppurativa. 1
Mechanism of Action
Secukinumab works by targeting a specific inflammatory pathway that is overactive in HS:
- IL-17A is elevated in HS lesions and plays a central role in perpetuating the chronic inflammation 1
- By binding to IL-17A, secukinumab prevents this cytokine from interacting with its receptor on immune and skin cells 1
- This blockade inhibits the release of pro-inflammatory cytokines and chemokines that would otherwise recruit more inflammatory cells and worsen disease 1
What Happens at the Tissue Level
When secukinumab blocks IL-17A in HS patients:
- Reduces epidermal neutrophil infiltration in affected skin areas 1
- Decreases IL-17A levels in lesional tissue 1
- Downregulates genes involved in keratinocyte differentiation and antimicrobial response that contribute to abnormal follicular occlusion 2
- Modulates epidermal development pathways that are dysregulated in HS 2
Clinical Translation
The molecular effects translate to meaningful clinical improvements:
- 75-87% of patients achieve HiSCR (Hidradenitis Suppurativa Clinical Response) by week 16-48 2, 3
- Significant reduction in nodule count, abscess formation, and draining tunnels 3
- Rapid pain relief, with most patients reporting ≥30% improvement in pain scores 2, 3
- Improved quality of life as measured by DLQI scores 3
Pharmacokinetics Relevant to HS
Important to understand that secukinumab's drug levels in HS patients differ slightly from other conditions:
- Mean steady-state trough concentrations are approximately 26% lower in HS patients compared to psoriasis patients 1
- Despite this, clinical efficacy remains robust, suggesting the IL-17A pathway is sufficiently blocked at these levels
- Steady-state is achieved by week 24 with the recommended dosing regimen 1
Why IL-17A Matters in HS
The rationale for targeting IL-17A specifically in HS is based on:
- Increased numbers of IL-17A-producing lymphocytes and innate immune cells found in HS patients' blood and lesions 1
- IL-17A drives the formation of the characteristic inflammatory nodules and promotes tissue destruction
- Unlike TNF-α inhibitors (like adalimumab), IL-17A blockade may offer an alternative pathway for patients who fail or lose response to anti-TNF therapy 4
Important Caveat
Secukinumab should be avoided or used with extreme caution in patients with inflammatory bowel disease (IBD), as new cases or exacerbations of Crohn's disease and ulcerative colitis have been reported with IL-17A inhibition 5. This is a critical safety consideration when selecting biologics for HS patients.
The drug is FDA-approved for HS at 300 mg monthly dosing (after loading), though some patients may benefit from every-2-week dosing based on clinical response 5, 1.